WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · HB 567

Legislative bill overview

HB 567 aims to ensure patient access to biomarker testing in North Carolina by establishing requirements for insurance coverage and removing barriers to these diagnostic tests. Biomarker testing identifies specific genetic or molecular characteristics that can guide personalized treatment decisions, particularly for cancer and other serious conditions. The bill likely addresses gaps where insurance companies deny coverage for these tests despite their clinical utility.

Why is this important

Biomarker testing can significantly improve treatment outcomes by enabling doctors to prescribe medications most likely to work for individual patients, reducing ineffective treatments and associated costs. Without coverage mandates, patients may face prohibitive out-of-pocket costs ($1,000-$5,000+ per test) or delayed diagnoses while awaiting insurance authorization. This bill directly affects healthcare equity, as cost barriers disproportionately impact lower-income patients who need these precision medicine advances most.

Potential points of contention

  • Insurance cost concerns: Insurers may argue that mandating biomarker testing coverage increases premiums for all policyholders, particularly if tests are ordered without clear clinical necessity
  • Scope and specificity: Disagreement over which biomarkers qualify for coverage and which medical conditions warrant testing, potentially leading to inconsistent application
  • Prior authorization requirements: Debate over whether the bill sufficiently limits insurance companies' ability to deny or delay testing through prior authorization processes, which can cause treatment delays

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.